Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.02 EUR | -0.50% | -3.74% | +29.38% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
May. 03 | AIB buys back EUR999 million worth of shares from Irish government | AN |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Banks
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+29.38% | 13.27B | B+ | ||
+15.97% | 566B | C+ | ||
+18.68% | 313B | C+ | ||
+14.40% | 252B | C+ | ||
+19.22% | 205B | C | ||
+20.22% | 182B | B- | ||
+26.17% | 169B | B- | ||
+8.25% | 161B | C+ | ||
+9.47% | 151B | B- | ||
+11.67% | 137B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A5G Stock
- Ratings AIB Group plc